Sorry, you need to enable JavaScript to visit this website.

ZINECARD® (dexrazoxane) Indications and Usage

1 INDICATIONS AND USAGE

ZINECARD is indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m2 and who will continue to receive doxorubicin therapy to maintain tumor control. Do not use with the initiation of doxorubicin therapy [see Warnings and Precautions (5.2)].

What's New

No Current Announcements.

Contact Pfizer Medical

Search

Please enter your search term(s) for ZINECARD®